cabazitaxel profile

cabazitaxel: an antineoplastic agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cabazitaxel : A tetracyclic diterpenoid that is 10-deacetylbaccatin III having O-methyl groups attached at positions 7 and 10 as well as an O-(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl group attached at position 13. Acts as a microtubule inhibitor, binds tubulin and promotes microtubule assembly and simultaneously inhibits disassembly. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	9854073
CHEMBL ID	1201748
CHEBI ID	63584
SCHEMBL ID	179674
MeSH ID	M0550309

Synonym
DB06772
cabazitaxel
txd 258
nsc-761432
cabazitaxel acetonate
CHEMBL1201748
txd-258
xrp-6258
jevtana
chebi:63584 ,
xrp 6258
183133-96-2
xrp6258
nsc761432
A25044
cabazitaxel (usan/inn)
D09755
rpr 116258a
cabazitaxel [usan:inn]
nsc 761432
taxoid xrp6258
cabazitaxel injection
1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-ene-2,4,13-triyl 4-acetate 2-benzoate 13-((2r,3s)-3-(((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate)
kabazitaxel
51f690397j ,
txd258
unii-51f690397j
jevtana kit
(((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-((2r,3s)-3-
HY-15459
CS-0972
NCGC00346704-01
(2alpha,5beta,7beta,10beta,13alpha)-4-acetoxy-13-({(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
cabazitaxelum
S3022
jevanta
gtpl6798
cabazitaxel [mart.]
cabazitaxel [mi]
cabazitaxel acetonate [jan]
cabazitaxel [orange book]
cabazitaxel [who-dd]
cabazitaxel [usan]
1-hydroxy-7.beta.,10.beta.-dimethoxy-9-oxo-5.beta.,20-epoxytax-11-ene-2.alpha.,4,13.alpha.-triyl 4-acetate 2-benzoate 13-((2r,3s)-3-(((tert-butoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate)
cabazitaxel [ema epar]
cabazitaxel [vandf]
cabazitaxel [inn]
4-acetoxy-13-((3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
BMQGVNUXMIRLCK-OAGWZNDDSA-N
SCHEMBL179674
AB01273971-01
(2ar,4s,4as,6r,9s,11s,12s,12ar,12bs)-12b-acetoxy-9-(((2r,3s)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1h-7,11-methanocyclodeca[3,4]be
AB01273971_02
DTXSID40171389 ,
(1s,2s,3r,4s,7r,9s,10s,12r,15s)-4-(acetyloxy)-15-{[(2r,3s)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate
J-519981
EX-A838
rpr-116258a
sr-01000941585
SR-01000941585-1
mfcd18827611
J-011721
AKOS032947285
Q412963
cabazitaxel (jevtana)
C3390
AS-75355
(1s,2s,3r,4s,7r,9s,10s,12r,15s)-4-(acetyloxy)-15-{[(2r,3s)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0(3),(1)?.0?,?]heptadec-13-en-2-yl benzoate
benzenepropanoic acid, beta-[[(1,1-dimethylethoxy)carbonyl]amino]-alpha-hydroxy-, (2ar,4s,4as,6r,9s,11s,12s,12ar,12bs)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-
(2ar,4s,4as,6r,9s,11s,12s,12ar,12bs)-12b-acetoxy-9-(((2r,3s)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,1
AMY4317
CCG-270519
xrp6258;rpr-116258a;taxoid xrp6258
NCGC00346704-03
nsc-794609
nsc794609
[(1s,2s,3r,4s,7r,9s,10s,12r,15s)-4-acetyloxy-1-hydroxy-15-[(2r,3s)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
EN300-22232477
(2alpha,5beta,7beta,10beta,13alpha)-4-acetoxy-13-(((2r,3s)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-((2r,3s)-3-(((tert-butoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate)
l01cd04
1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-((2r,3s)-3-(((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate)
dtxcid1093880
cabazitaxel (mart.)

Excerpt	Reference	Relevance
"Cabazitaxel (CTX) is an anti-neoplastic agent of second-generation taxane derivatives, characterized by very low water solubility. "	( Synthesis, cytotoxicity assay, pharmacokinetics, biodistribution and modeling study of cabazitaxel-dextran nanoconjugates: targeted vs non targeted delivery. Ahmadi, F; Daneshamouz, S; Parhizkar, E; Parhizkar, G; Sakhteman, A; Samani, SM, 2022)	2.39
"Cabazitaxel is an effective treatment of post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). "	( Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis. Egawa, S; Karakiewicz, PI; Kawada, T; Kimura, T; König, F; Laukhtina, E; Mostafaei, H; Motlagh, RS; Nyirady, P; Pallauf, M; Pradere, B; Quhal, F; Rajwa, P; Shariat, SF; Yanagisawa, T, 2023)	2.56
"Cabazitaxel is a next-generation taxane that can prolong overall survival after docetaxel treatment in patients with metastatic castration-resistant prostate cancer. "	( Efficacy of cabazitaxel in patients with metastatic castration-resistant prostate cancer: A single-center study in Japan. Hayashi, T; Ishii, M; Kakimoto, KI; Kawamura, N; Nagahara, A; Nakai, Y; Nakayama, M; Nishimura, K; Yamamoto, Y; Yoshimura, A, 2023)	2.73
"Cabazitaxel is a highly effective drug used as second-line chemotherapy following docetaxel, and it causes fewer adverse effects compared with docetaxel."	( [LONG TERM ADMINISTRATION OF RELATIVE DOSE INTENSITY-ADJUSTED CABAZITAXEL FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A CASE REPORT]. Hakamata, Y; Imai, S; Kanda, Y; Sugiura, K; Yoneda, T, 2022)	1.68
"Cabazitaxel (CBZ) is a next-generation semi-synthetic taxane derivative that is effective in both preclinical models of human tumors that are sensitive or resistant to chemotherapy and in patients suffering from progressive prostate cancer despite docetaxel treatment."	( Cabazitaxel's ototoxicity: An animal study and histopathologic research. Bucak, A; Günebakan, Ç; Kahveci, OK; Kınar, A; Kuzu, S; Özdemir, Ç; Ulu, Ş, 2023)	3.07
"Cabazitaxel is an alternative to PSMA radioligand therapy after failure of novel hormonal therapy (NHT) and docetaxel."	( [Role of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) treatment: still standard or exception?] Thomas, C, 2023)	1.63
"Cabazitaxel (CTX) is a medication used for treating metastatic prostate cancer. "	( Influence of unsaturated fatty acids on the antitumor activity of polymeric conjugates grafted with cabazitaxel against prostate cancer. Dong, P; Hu, J; Jia, W; Li, X; Liu, J; Lv, H; Shi, Y; Wang, S; Yang, L; Zhao, L, 2023)	2.57
"Cabazitaxel is a treatment of metastatic castration-resistant prostate cancer (mCRPC) after docetaxel failure. "	( Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort. Balestra, A; Droz-Perroteau, C; Fizazi, K; Fourrier-Reglat, A; Guiard, E; Joly, F; Jove, J; Lacueille, C; Lamarque, S; Moore, N; Oudard, S; Rouyer, M; Tubach, F, 2019)	2.22
"Cabazitaxel is a novel taxane that might be active in breast cancer resistant to first-generation taxanes."	( Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial. Chryssogonidis, I; Dimopoulos, MA; Fountzilas, G; Kalofonos, HP; Kentepozidis, NK; Koliou, GA; Kotsakis, A; Koumakis, G; Koutras, A; Lazaridis, G; Psoma, E; Psyrri, A; Razis, E; Res, E; Tryfonopoulos, D; Zagouri, F, 2020)	2.34
"Cabazitaxel (CTX) is a promising anticancer drug. "	( Microfluidic self-assembly of high cabazitaxel loading albumin nanoparticles. Dong, S; Lee, RJ; Meng, F; Sun, Y; Teng, L; Wang, G; Zheng, X, 2020)	2.28
"Cabazitaxel (CBZ) is a new taxane-based antitumor drug approved by the FDA for the treatment of prostate cancer, especially for patients with advanced prostate cancer for whom docetaxel is ineffective or causes aggravation. "	( Preparation and Evaluation of Cabazitaxel-Loaded Bovine Serum Albumin Nanoparticles for Prostate Cancer. Wan, Z; Wang, L; Xie, F; Zhang, G; Zhang, H, 2020)	2.29
"Cabazitaxel is a new taxane that has demonstrated beneficial effect in prostate cancer patients resistant to docetaxel."	( Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer. Adimi, P; Jakobsen, A; Madsen, CV; Steffensen, KD, 2020)	2.72
"Cabazitaxel (CBZ) is a taxane derivative and an anti-microtubule agent effective against numerous cancers including drug-resistant cancers. "	( Design and evaluation of cabazitaxel loaded NLCs against breast cancer cell lines. Badduri, N; Bettada, VG; Chand, P; Dey, S; Gupta, NV; Jain, V; Kesharwani, SS; Kumar, H; Madhunapantula, SV, 2021)	2.37
"Cabazitaxel is unlikely to be a cost-effective treatment option compared with ASTIs in patients with mCRPC previously treated with docetaxel who had progression within 12 months while receiving ASTIs."	( Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance. Li, Q; Xie, D; Zhang, PF, 2021)	2.35
"Cabazitaxel is a second-generation taxane developed to overcome resistance to docetaxel and is approved for the treatment of patients with mCRPC previously treated with a docetaxel-containing regimen."	( Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer. Corman, S; Drea, E; Flannery, K; Gao, X; Hudspeth, L; Miao, R; Xue, M, 2017)	1.5
"Cabazitaxel is a taxane with activity in docetaxel-refractory cancers."	( A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). Anido, U; Bellmunt, J; Collado, R; De Wit, R; Fernández Calvo, O; González Graguera, MB; González Larriba, JL; González-Billalabeitia, E; Grande, E; Kerst, JM; Los, M; Maciá, S; Medina, A; Morales-Barrera, R; Perez-Gracia, JL; Pujol, E; Rubio, G; Van den Eertwegh, AJM; Vázquez, F, 2017)	1.45
"Cabazitaxel is a next generation taxane that has been shown to improve overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed during or after docetaxel-based therapy. "	( Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program. Guminski, A; Gurney, H; Ng, S; Parente, P; Parnis, F, 2017)	3.34
"Cabazitaxel is a novel taxane approved for treatment of metastatic hormone-refractory prostate cancer in patients pretreated with docetaxel. "	( βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel. Azarenko, O; Jordan, MA; LaPointe, NE; Miller, H; Rifkind, A; Smiyun, G; Wilson, L, 2017)	2.18
"Cabazitaxel is an important treatment option after docetaxel progression. "	( [Metastatic castration-resistant prostate cancer : Use of cabazitaxel taking into consideration current data]. Albers, P; Bögemann, M; Goebell, P; Gschwend, JE; Heidenreich, A; Klier, J; König, F; Machtens, S; Pantel, K; Thomas, C, 2018)	2.17
"Cabazitaxel is a second-generation semisynthetic taxane. "	( Cabazitaxel inhibits proliferation and potentiates the radiation response of U87MG glioblastoma cells. Mousavizadeh, K; Neshasteh-Riz, A; Safa, M; Zeinizade, E, 2018)	3.37
"Cabazitaxel (CTX) is a taxoid drug and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of TNF superfamily."	( Synthesis, characterization, and in vitro evaluation of TRAIL-modified, cabazitaxel -loaded polymeric micelles for achieving synergistic anticancer therapy. Chi, L; Feng, C; Gong, F; Han, X; Shen, Y; Sun, J, 2018)	1.43
"Cabazitaxel is a new generation taxane showing lesser drug resistance when compared with previous ones."	( Optic atrophy after cabazitaxel treatment in a patient with castration-resistant prostate cancer: a case report. Diker, Ö; Diker, S, 2019)	1.56
"Cabazitaxel, which is a novel semi-synthetic anti-cancerous agent, is newly approved for the treatment of metastatic castration resistant prostate cancer(CRPC). "	( [Safety Profile of the Combination of Prophylactic Pegfilgrastim and Cabazitaxel for Japanese Patients with Castration Resistant Prostate Cancer]. Aoyama, T; Azuma, K; Hama, T; Hashimoto, K; Kawakami, K; Sugisaki, T; Suzuki, K; Yonese, J; Yuasa, T, 2018)	2.16
"Cabazitaxel is a cytotoxic drug that interferes with mitosis by acting on tubulin."	( Coupling the near-infrared fluorescent dye IR-780 with cabazitaxel makes renal cell carcinoma chemotherapy possible. Chen, G; He, W; Hou, G; Lan, T; Lu, Z; Meng, P; Wang, F; Wei, D; Yan, F; Yang, X; Yuan, J; Zhang, G; Zheng, Y; Zhu, Z, 2019)	1.48
"Cabazitaxel is an efficacious treatment for patients with metastatic castration-resistant prostate cancer who have previously progressed on docetaxel, but febrile neutropenia during the first cycle is a frequent complication. "	( Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan. Ecstein-Fraisse, E; Fukasawa, S; Harada, K; Hayashi, N; Kosaka, T; Oya, M; Sugimoto, M; Sumitomo, M; Sunaga, Y; Uemura, H; Yoshimura, K, 2019)	2.17
"Cabazitaxel is a novel taxane that is approved for use in metastatic castration-resistant prostate cancer based on the Phase III TROPIC study, which showed improved overall survival with cabazitaxel/prednisone versus mitoxantrone/prednisone. "	( Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Basso, U; Boccardo, F; Bortolus, R; Bracarda, S; Cartenì, G; Chiuri, V; Di Lorenzo, G; Dondi, D; Fornarini, G; Fratino, L; Gasparro, D; Gernone, A; Marchetti, P; Mattioli, R; Mazzanti, R; Messina, C; Pinto, C; Procopio, G; Ronzoni, M; Scotto, T; Tucci, M, 2014)	2.23
"Cabazitaxel is an effective second line cytotoxic agent that improves survival; studies are underway comparing cabazitaxel to docetaxel as first line chemotherapy."	( Practical guide to the use of chemotherapy in castration resistant prostate cancer. Petrylak, DP, 2014)	1.12
"Cabazitaxel is a second-generation taxane with in vivo activity against taxane-sensitive and -resistant tumor cell lines and tumor xenografts. "	( Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors. Barber, SL; Dedieu, JF; Kassalow, L; Lane, AR; Lockhart, AC; Mita, AC; Mita, MM; Moseley, JL; Sarantopoulos, J; Sundaram, S; Wack, C; Wang-Gillam, A, 2014)	2.13
"Cabazitaxel is a novel second-generation taxane developed to overcome such resistance."	( Preclinical profile of cabazitaxel. Benning, V; Beys, E; Bouchard, H; Gupta, S; Semiond, D; Vrignaud, P, 2014)	1.43
"Cabazitaxel is a semisynthetic taxane approved for the treatment of patients with hormone-refractory metastatic prostate cancer (now known as metastatic castration-resistant prostate cancer) treated previously with a docetaxel-containing treatment regimen. "	( A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors. Clive, S; Fontaine, H; Kelly, L; Mauriac, C; Oprea, C; Ridoux, L; Sanderink, GJ; Sémiond, DR; Vincent, C, 2015)	2.1
"Cabazitaxel is an anticancer drug and its marketed product (form A) is acetone solvate (1:1) (Didier E, Perrin MA. "	( Isostructurality among solvates of cabazitaxel: X-ray structures and new solvates preparation. Du, G; Gong, N; He, L; Lu, Y; Xu, W; Yang, S; Zhang, N, 2015)	2.14
"Cabazitaxel is a second line chemotherapy drug recently approved for the treatment of metastatic castration-resistant prostate cancer. "	( Formal consensus method to evaluate the conformity of prescription of a recently approved chemotherapy treatment in an observatory study. Bellera, C; Houédé, N; Leutenegger, E; Lomma, M, 2015)	1.86
"Cabazitaxel is a novel taxane that differs from paclitaxel by its lower affinity for ATP-binding cassette (ABC) transporters."	( ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel. Alqahtani, S; Ambudkar, SV; Ashby, CR; Chen, ZS; Kaddoumi, A; Kathawala, RJ; Shukla, S; Wang, YJ; Zhang, YK, 2015)	1.35
"Cabazitaxel is a second-line taxane chemotherapeutic agent that provides additional survival benefits to patients with advanced disease."	( Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer. Cao, Z; Horbinski, C; Kyprianou, N; Martin, SK; Penticuff, JC; Pu, H, 2016)	1.38
"Cabazitaxel is an approved second-line treatment for docetaxel-refractory metastatic castration-resistant prostate cancer. "	( Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer. Claros, M; Nathanson, L; Ramachandran, K; Singal, R; Speer, C, 2016)	2.17
"Cabazitaxel is a next generation semi-synthetic taxane derivative, which is effective in both preclinical models of human tumors sensitive or resistant to chemotherapy and in patients with progressive prostate cancer despite docetaxel treatment."	( Cabazitaxel causes a dose-dependent central nervous system toxicity in rats. Aksit, H; Atalay, T; Boyaci, MG; Gonul, Y; Guven, M; Karademir, M; Karavelioglu, E; Rakip, U; Simsek, N, 2016)	2.6
"Cabazitaxel (CTX) is a second-generation semisynthetic taxane that demonstrates antitumor activity superior to docetaxel. "	( A novel cabazitaxel-loaded polymeric micelle system with superior in vitro stability and long blood circulation time. Chen, D; Gong, F; Han, X; Li, D; Shen, Y; Sun, J; Zhou, J, 2016)	2.31
"Cabazitaxelis a taxane-type antineoplastic agent used for treating prostate cancer. "	( [An Undeniable Case of Optic Neuropathy Due to Cabazitaxel]. Kaneko, M; Kawara, H; Kawashima, Y; Nakauchi, H; Noguchi, Y; Tokuyama, Y, 2016)	2.13
"Cabazitaxel (CBX) is an effective antineoplastic agent for the treatment of many kinds of cancers. "	( Cabazitaxel and indocyanine green co-delivery tumor-targeting nanoparticle for improved antitumor efficacy and minimized drug toxicity. Gao, H; He, Q; Liu, Y; Ruan, S; Shi, K; Tai, X; Wang, Y; Yang, Y; Zhang, L; Zhang, Z, 2017)	3.34
"Cabazitaxel (CBZ) is a new taxane approved by FDA for treatment of castration- resistant prostate cancer not responding to docetaxel. "	( Targeted Delivery of Cabazitaxel by Conjugation to Albumin-PEG-folate Nanoparticles Using a Cysteine-acrylate Linker and Simple Synthesis Conditions. Amini, M; Atyabi, F; Behrouz, H; Dinarvand, R; Esfandyari-Manesh, M; Khoeeniha, MK; Varnamkhasti, BS, 2017)	2.22
"Cabazitaxel (CTX) is a second- generation taxane derivative, a class of potent anticancer drugs with very low water solubility. "	( Synthesis and Characterization of Water-soluble Conjugates of Cabazitaxel Hemiesters-Dextran. Ahmadi, F; Daneshamouz, S; Mohammadi-Samani, S; Parhizkar, E; Parhizkar, G; Sakhteman, A, 2017)	2.14
"Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers. "	( Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Bodrogi, I; de Bono, JS; Gravis, G; Gupta, S; Hansen, S; Kocak, I; Machiels, JP; Mackenzie, MJ; Oudard, S; Ozguroglu, M; Roessner, M; Sartor, AO; Shen, L, 2010)	2.15
"Cabazitaxel is a new taxane characterized by convenient administration, a favorable pharmacokinetic and safety profile and a decreased propensity for P-glycoprotein (Pgp)-mediated drug resistance. "	( Cabazitaxel, a new taxane with favorable properties. Bouchet, BP; Galmarini, CM, 2010)	3.25
"Cabazitaxel (XRP6258) is a new taxoid that is active in chemotherapy-resistant tumour cell lines."	( A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Awada, A; Besse, T; Campone, M; Dubin, F; Machiels, JP; Magherini, E; Pivot, X; Semiond, D; Villanueva, C, 2011)	1.36
"Cabazitaxel seems to be a promising second-line therapy in CRPC."	( Cabazitaxel for the treatment of prostate cancer. Braeckman, JG; Denis, L; Michielsen, DP, 2011)	2.53
"Cabazitaxel is a novel tubulin-binding taxane that differs from docetaxel because of its poor affinity for P-glycoprotein (P-gp), an ATP-dependent drug efflux pump."	( Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Antonarakis, ES; Paller, CJ, 2011)	2.53
"Cabazitaxel is a novel taxane active in both preclinical models of chemotherapy-sensitive and -resistant human tumours and patients with advanced prostate cancer that progressed following docetaxel treatment."	( Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study. Assadourian, S; Delva, R; Diéras, V; Girre, V; Laurence, V; Livartowski, A; Lortholary, A; Pierga, JY; Semiond, D, 2013)	2.55
"Cabazitaxel (Cbz) is an approved second-line treatment in metastatic castration-resistant prostate cancer (mCRPC) following docetaxel therapy with a significant survival benefit compared with mitoxantrone. "	( Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Albers, P; Arsov, C; Bokemeyer, C; Ecstein-Fraisse, E; Gschwend, J; Heidenreich, A; Heinrich, E; Honecker, F; Keck, B; Miller, K; Müller, SC; Otremba, B; Pfister, D; Retz, M; Rogenhofer, S; Scholz, HJ; Steiner, U; Trojan, L; Volkmer, B; Wirth, M, 2013)	3.28

Excerpt	Reference	Relevance
"Cabazitaxel has a manageable toxicity profile but is poorly active as second/third-line treatment in advanced ACC patients. "	( Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma. Abate, A; Ambrosini, R; Berruti, A; Canu, L; Cosentini, D; Ferrari, VD; Gianoncelli, A; Grisanti, S; Laganà, M; Sigala, S; Terzolo, M; Tiberio, GAM; Turla, A; Zamparini, M, 2022)	2.5
"Cabazitaxel has a high rate of protein binding; moreover, serum albumin levels<3.6 g/dL might be associated with high concentrations of unbound cabazitaxel, and thus an increase in the incidence of GradeB3 neutropenia."	( [Identification of the Risk Factors for Cabazitaxel-Induced Neutropenia with Preventive Administration of Pegfilgrastim]. Ando, N; Asano, K; Harada, D; Kageyama, A; Kawakubo, T; Kitamura, M; Nakazawa, Y, 2019)	1.5
"Cabazitaxel (CAB) has been effectively used for the treatment of metastatic castration-resistant prostate cancer (mCRPC)."	( Immunotherapeutic role of cabazitaxel treatment in the activation of TLR3 signalling in metastatic castration-resistant prostate cancer in vitro. Deveci Ozkan, A; Guney Eskiler, G; Kaleli, S; Sahin, E, 2022)	1.74
"Cabazitaxel has been shown to improve overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients after docetaxel in the TROPIC trial. "	( Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. Bergman, AM; Bloemendal, HJ; Coenen, JLLM; de Wit, R; Fossion, LMCL; Gerritsen, WR; Hendriks, MP; Kuppen, MCP; Mehra, N; Polee, MB; Ten Bokkel Huinink, D; Uyl-de Groot, CA; van de Luijtgaarden, ACM; van den Berg, HPP; van den Bergh, ACMF; van den Bosch, J; van den Eertwegh, AJM; van Oort, IM; Weijl, N; Westgeest, HM, 2019)	2.34
"Cabazitaxel has shown preclinical activity in platinum-resistant GCT models."	( Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series. Bokemeyer, C; Dieing, A; Gläser, D; Hentrich, M; Lorch, A; Ochsenreither, S; Oing, C; Pereira, RR; Richter, S; Rumpold, H; Seidel, C; Zschäbitz, S, 2020)	1.52
"Cabazitaxel has been demonstrated to improve the overall survival for men with metastatic castrate-resistant prostate cancer. "	( Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer. Den, RB; Dicker, AP; Gomella, LG; Greenspan, J; Hoffman-Censits, JH; Hurwitz, MD; Kelly, WK; Lallas, CD; Leiby, B; Lin, J; Showalter, TN; Trabulsi, EJ, 2020)	2.31
"Cabazitaxel has been approved as the second line treatment to docetaxel in mCRPC."	( Pharmacotherapeutic strategies for castrate-resistant prostate cancer. Abou Chakra, M; Dellis, A; Moussa, M; Papatsoris, A; Sryropoulou, D, 2020)	1.28
"Cabazitaxel has shown the ability to overcome drug resistance induced by paclitaxel and docetaxel; however, substantially high toxicity has been observed in patients receiving this agent, which compromises its efficacy."	( Akt inhibition improves the efficacy of cabazitaxel nanomedicine in preclinical taxane-resistant cancer models. Chen, W; Chen, X; Hu, X; Li, T; Wan, J; Wang, H, 2021)	1.61
"Cabazitaxel has been reimbursed as a second-line therapy for patients with metastatic castrate-resistant prostate cancer (mCRPC) in the Netherlands since 2011. "	( Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands. Bergman, AM; Coenen, JL; Gelderblom, H; Gerritsen, WR; van den Eertwegh, AJ; van Oort, IM; Wissing, MD, 2013)	3.28
"Cabazitaxel (Jevtana) has been approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). "	( Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells. Chen, Z; Chi, A; Iqbal, S; Kim, S; Kucuk, O; Ritenour, C; Wang, Y; Wang, YA; Wu, D; Zhang, S, 2013)	2.11
"Cabazitaxel has been shown to improve overall survival in this setting."	( Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel. Afonso, J; Antón Aparicio, LM; Campos, B; Fernández, O; Lázaro, M; León, L; Vázquez, S, 2014)	1.36
"Cabazitaxel/prednisone has been shown to prolong survival versus mitoxantrone/prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or after docetaxel. "	( Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Bracarda, S; Climent, MA; Fossa, S; Heidenreich, A; Hitier, S; Mason, M; Ozen, H; Papandreou, C; Sengelov, L; Van Oort, I, 2014)	2.25
"Cabazitaxel and AA have been approved by the US Food and Drug Administration for use after docetaxel in mCRPC. "	( Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer. Berger, R; Frank, SJ; Gez, E; Hanovich, E; Hayat, H; Keizman, D; Kovel, S; Neiman, V; Peer, A; Rosenbaum, E; Sella, A; Sella, T; Sharide, D, 2014)	2.22
"Cabazitaxel has been reported to have activity superior to that of docetaxel in preclinical models of multidrug-resistant adult cancers, and it was active in patients who had progressed on or after docetaxel."	( Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program. Gorlick, R; Houghton, PJ; Kang, MH; Kolb, EA; Kurmasheva, RT; Maris, JM; Reynolds, CP; Smith, MA; Wu, J, 2015)	1.38
"Cabazitaxel has been used to treat castration-resistant prostate cancer since its approval by the US Food and Drug Administration in 2010. "	( Cabazitaxel-induced autophagy via the PI3K/Akt/mTOR pathway contributes to A549 cell death. Bai, B; Huo, R; Liu, P; Liu, X; Shi, C; Wang, L; Wei, S; Zhang, C; Zhang, H; Zhao, Y, 2016)	3.32
"Cabazitaxel has been shown to be well tolerated and has been approved in Europe and the USA as second-line chemotherapy for mCRPC."	( Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies. Bahl, A; Bellmunt, J; Oudard, S, 2012)	1.1
"The cabazitaxel, Jevtana(®), has been approved in second line after docetaxel."	( [Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer]. Joly, F; Lheureux, S, 2012)	1.77

Excerpt	Reference	Relevance
"Cabazitaxel at lower (20 mg/sqm) dose was associated with poorer outcomes in AR-V7 positive patients compared to AR-V7 negative patients in a post hoc subgroup analysis."	( Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel. Banna, GL; Basso, U; Bondi, I; Brighi, N; Conteduca, V; De Giorgi, U; Fornarini, G; Gurioli, G; Lolli, C; Mosca, A; Nicodemo, M; Ravaglia, G; Scarpi, E; Schepisi, G; Ulivi, P, 2022)	1.64

Excerpt	Reference	Relevance
"Cabazitaxel is a treatment of metastatic castration-resistant prostate cancer (mCRPC) after docetaxel failure. "	( Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort. Balestra, A; Droz-Perroteau, C; Fizazi, K; Fourrier-Reglat, A; Guiard, E; Joly, F; Jove, J; Lacueille, C; Lamarque, S; Moore, N; Oudard, S; Rouyer, M; Tubach, F, 2019)	2.22
"Cabazitaxel could be a treatment option for CRPC in patients aged ≥80 years based on its safety and efficacy profiles. "	( Cabazitaxel in patients aged ≥80 years with castration-resistant prostate cancer: Results of a post-marketing surveillance study in Japan. Kazama, H; Matsubara, N; Matsuyama, H; Seto, T; Suzuki, K; Tsukube, S, 2020)	3.44
"Cabazitaxel treatment also leads to downregulation of the microtubule-depolymerizing mitotic kinesins, MCAK, and HSET, preventing their ability to depolymerize microtubules and thus enhancing sensitivity to taxane treatment."	( Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. Kyprianou, N; Martin, SK, 2015)	1.14
"Cabazitaxel treatment showed a strong inhibitory effect on colony formation capacity."	( Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells. Bokemeyer, C; Dyshlovoy, S; Gerwing, M; Hauschild, J; Honecker, F; Jacobsen, C; Oechsle, K; Oing, C; Oldenburg, J; Rohlfing, T; Venz, S; von Amsberg, G, 2016)	2.6
"When treated with cabazitaxel, the molecular and phenotypic signatures of macrophages were polarized toward M1 state, and the NF-kB signaling pathway became activated."	( Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer. Cao, X; Chen, J; Chen, S; Dang, J; Feng, M; Gunes, EG; Li, B; Muend, S; Querfeld, C; Raoof, M; Rosen, ST; Tian, L; Wang, Y; Xu, B; Yu, J, 2021)	1.35
"Treatment with cabazitaxel after > 10 cycles of docetaxel may be an appropriate option when it can be administered."	( Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study. Eto, M; Harano, M; Hasegawa, S; Kuroiwa, K; Nakamura, M; Sakamoto, N; Seki, N; Shiota, M; Tomoda, T; Yokomizo, A; Yunoki, T, 2019)	1.16
"Treatment with cabazitaxel was prognostic for survival ≥2 years."	( Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Bahl, A; de Bono, JS; Devin, J; Gravis, G; Hansen, S; Kocak, I; Oudard, S; Ozgüroglu, M; Sartor, AO; Shen, L; Tombal, B, 2013)	1.13
"Treatment with cabazitaxel might cause less alopecia, nail changes, neuropathy, and dysgeusia compared with docetaxel."	( Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. Cathomas, R; De Bono, JS; Gillessen, S; Omlin, A; Rothermundt, C; Sartor, O; Shen, L; Su, Z, 2015)	0.97
"Treatment with cabazitaxel plus prednisone has important clinical antitumour activity, improving overall survival in patients with metastatic castration-resistant prostate cancer whose disease has progressed during or after docetaxel-based therapy."	( Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Bodrogi, I; de Bono, JS; Gravis, G; Gupta, S; Hansen, S; Kocak, I; Machiels, JP; Mackenzie, MJ; Oudard, S; Ozguroglu, M; Roessner, M; Sartor, AO; Shen, L, 2010)	1.06
"Treatment with cabazitaxel plus prednisone has improved overall survival of 2.4 months compared to mitoxantrone in the TROPIC phase III."	( [Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer]. Joly, F; Lheureux, S, 2012)	1.63

Excerpt	Reference	Relevance
" Most common adverse events (AEs) associated with cabazitaxel were hematologic; the rates (all grade) of neutropenia, leukopenia, and anemia were greater than 90%."	( Managing side effects of the novel taxane cabazitaxel in castrate-resistant prostate cancer. Doyle-Lindrud, S, 2012)	0.9
" The most common grade 3/4 adverse events were neutropenia (33."	( Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Basso, U; Boccardo, F; Bortolus, R; Bracarda, S; Cartenì, G; Chiuri, V; Di Lorenzo, G; Dondi, D; Fornarini, G; Fratino, L; Gasparro, D; Gernone, A; Marchetti, P; Mattioli, R; Mazzanti, R; Messina, C; Pinto, C; Procopio, G; Ronzoni, M; Scotto, T; Tucci, M, 2014)	0.79
" Number of cabazitaxel cycles, dose reductions for any cause, dose delays possibly related to cabazitaxel adverse events, and tolerability were similar in the three age groups."	( Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Bracarda, S; Climent, MA; Fossa, S; Heidenreich, A; Hitier, S; Mason, M; Ozen, H; Papandreou, C; Sengelov, L; Van Oort, I, 2014)	1.19
" Even though these taxanes display a favorable toxicity profile, their routine use in clinical practice requires knowledge about the most frequent and distinct adverse events that may result from their administration."	( Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity. Buzaid, AC; Sartor, O; Schutz, FA, 2014)	0.4
"This study assessed the cardiovascular safety of cabazitaxel, based on thorough evaluation of QT and non-QT variables, and the relationship between pharmacokinetic and pharmacodynamic electrocardiographic (ECG) profiles and the occurrence of Grade ≥3 cardiovascular adverse events."	( An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors. Agarwala, SS; Baron, A; Chadjaa, M; Conkright, W; Dakhil, S; Daugaard, G; Machiels, JP; Maison-Blanche, P; Millard, F; Rottey, S; Sémiond, D; Sengeløv, L; Sharma, S; Shen, L; Soetekouw, PM; Van Veldhuizen, P; Wade, JL; Yachnin, J, 2014)	0.89
" No Grade ≥3 cardiac adverse events were observed; Grade ≥3 hypotension and lymphocele occurred in two patients and one patient, respectively."	( An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors. Agarwala, SS; Baron, A; Chadjaa, M; Conkright, W; Dakhil, S; Daugaard, G; Machiels, JP; Maison-Blanche, P; Millard, F; Rottey, S; Sémiond, D; Sengeløv, L; Sharma, S; Shen, L; Soetekouw, PM; Van Veldhuizen, P; Wade, JL; Yachnin, J, 2014)	0.64
"These results suggest that cabazitaxel has no clinically significant cardiovascular adverse effects in patients with advanced solid tumors."	( An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors. Agarwala, SS; Baron, A; Chadjaa, M; Conkright, W; Dakhil, S; Daugaard, G; Machiels, JP; Maison-Blanche, P; Millard, F; Rottey, S; Sémiond, D; Sengeløv, L; Sharma, S; Shen, L; Soetekouw, PM; Van Veldhuizen, P; Wade, JL; Yachnin, J, 2014)	0.94
" Adverse events (AEs) possibly related to cabazitaxel occurred in 143 (93."	( Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program. Antón Aparicio, LM; Batista, N; Castellano, D; Esteban, E; Germà, JR; Luque, R; Maroto, P; Méndez-Vidal, MJ; Pérez-Valderrama, B; Sánchez-Hernández, A, 2014)	2.11
"25) or in frequencies of adverse events between these two treatments."	( [Clinical efficacy and safety of enzalutamide in metastatic castration-resistant prostate cancer: systematic review and meta-analysis]. Baji, P; Berczi, C; Brodszky, V; Géczi, L; Gulácsi, L; Péntek, M; Rencz, F; Szûcs, M, 2014)	0.4
"We hypothesized that the adverse event (AE) profile of cabazitaxel with regard to alopecia, nail changes, neuropathy, and dysgeusia differs from docetaxel."	( Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. Cathomas, R; De Bono, JS; Gillessen, S; Omlin, A; Rothermundt, C; Sartor, O; Shen, L; Su, Z, 2015)	0.86
" Secondary outcomes were radiographic progression-free survival (rPFS) and severe adverse effects (grade 3 or higher)."	( Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis. Cleves, A; Magri, V; Marras, E; Monti, E; Perletti, G; Rennie, PS; Trinchieri, A, 2015)	0.42
" Large-scale studies are also necessary to evaluate the impact of relevant toxic effects observed in a limited number of patients (e."	( Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis. Cleves, A; Magri, V; Marras, E; Monti, E; Perletti, G; Rennie, PS; Trinchieri, A, 2015)	0.42
" Direct toxic effect or metabolic derangement of chemotherapeutic agents may cause these complications."	( Cabazitaxel causes a dose-dependent central nervous system toxicity in rats. Aksit, H; Atalay, T; Boyaci, MG; Gonul, Y; Guven, M; Karademir, M; Karavelioglu, E; Rakip, U; Simsek, N, 2016)	1.88
" The influence of selected variables on the most relevant adverse events identified was assessed using a Generalized Estimating Equations model at univariate and multivariate analysis."	( Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. Bosso, D; Bracarda, S; Buonerba, C; De Placido, S; Di Lorenzo, G; Dondi, D; Gasparro, D; Gernone, A; Lucarelli, G; Messina, C; Puglia, L; Sonpavde, G; Zagonel, V, 2016)	0.7
" We suggest that cabazitaxel is a safe and effective treatment option for mCRPC patients who progress after docetaxel."	( Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology). Akman, T; Akyol, M; Araz, M; Arpacı, E; Avcı, N; Aydın, D; Bozkurt, O; Doğu, GG; Ergen, S; Hacıoğlu, MB; Harputlu, H; İmamoğlu, GI; Kaçan, T; Karaağaç, M; Kefeli, U; Koca, D; Menekşe, S; Pilancı, KN; Sevinç, A; Süner, A; Urakçı, Z; Yazıcı, ÖK, 2016)	1.07
"4%) experienced grade ≥3 treatment-emergent adverse events (TEAEs); the most frequent TEAEs were neutropenia, febrile neutropenia, diarrhoea, and vomiting."	( Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program. Guminski, A; Gurney, H; Ng, S; Parente, P; Parnis, F, 2017)	1.9
"2%) in the paclitaxel arm had at least one serious adverse event (p < 0."	( Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). Blohmer, JU; Burchardi, N; Denkert, C; Eiermann, W; Engels, K; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Klare, P; Kümmel, S; Loibl, S; Paepke, S; Schem, C; Schneeweiss, A; Untch, M; von Minckwitz, G, 2017)	0.68
" We analyzed the main outcomes, including the overall survival (OS), progression-free survival (PFS), prostate-specific antigen (PSA) response, tumor response and severe adverse events (AEs)."	( The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis. Huang, C; Song, P; Wang, Y, 2018)	0.74
" These results suggest that attaching flexible lipid chains to the highly toxic cabazitaxel generates a new drug entity that is more compatible with Tween 80-based formulations than its free drug form."	( Chemical Derivatization of the Anticancer Agent Cabazitaxel Using a Polyunsaturated Fatty Acid for Safe Drug Delivery Li, T; Lu, Z; Qiao, Y; Ren, L; Wan, J; Wang, H; Wu, J; Xie, H; Zheng, S; Zhou, L, 2018)	0.96
" Regarding non-hematological adverse events, no unknown adverse events were observed."	( [Safety Profile of the Combination of Prophylactic Pegfilgrastim and Cabazitaxel for Japanese Patients with Castration Resistant Prostate Cancer]. Aoyama, T; Azuma, K; Hama, T; Hashimoto, K; Kawakami, K; Sugisaki, T; Suzuki, K; Yonese, J; Yuasa, T, 2018)	0.72
" The oncological outcomes and adverse events (AEs) were documented, and prognostic factors for oncological outcomes and predictive factors for AEs were analysed."	( Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study. Eto, M; Harano, M; Hasegawa, S; Kuroiwa, K; Nakamura, M; Sakamoto, N; Seki, N; Shiota, M; Tomoda, T; Yokomizo, A; Yunoki, T, 2019)	0.82
" The oncological outcomes and adverse events were compared between 16 (25."	( Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study. Eto, M; Harano, M; Hasegawa, S; Kuroiwa, K; Nakamura, M; Sakamoto, N; Seki, N; Shiota, M; Tomoda, T; Yokomizo, A; Yunoki, T, 2019)	0.8
" The incidences of severe adverse events were also similar between the 3-weekly and 4-weekly regimens."	( Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study. Eto, M; Harano, M; Hasegawa, S; Kuroiwa, K; Nakamura, M; Sakamoto, N; Seki, N; Shiota, M; Tomoda, T; Yokomizo, A; Yunoki, T, 2019)	0.8
" Adverse drug reactions (ADRs) were evaluated according to CTCAE ver."	( Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study. Kazama, H; Matsubara, N; Matsuyama, H; Seto, T; Suzuki, K; Tsukube, S, 2019)	0.82
" Our results suggest that a hydrophobic and highly toxic drug can be rationally converted into a pharmacologically efficient and self-deliverable nanotherapy."	( Self-assembling poly(ethylene glycol)-block-polylactide-cabazitaxel conjugate nanoparticles for anticancer therapy with high efficacy and low in vivo toxicity. Cen, B; Lian, X; Liu, J; Shuai, Q; Su, W; Wan, J; Wang, H; Zhang, W; Zhao, G, 2020)	0.8
"Cabazitaxel, used in patients with metastatic castration-resistant prostate cancer (mCRPC), is associated with adverse events which may require dose reductions or discontinuation of treatment."	( The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer. Agema, BC; Belderbos, BPS; Bins, S; de Wit, R; de With, M; El Bouazzaoui, S; Mathijssen, RHJ; Oomen-de Hoop, E; Singh, RK; van Schaik, RHN, 2020)	2.22
"In this study, SLCO1B1 (SLCO1B115 and SLCO1B11B) was associated with cabazitaxel-induced adverse events in mCRPC patients."	( The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer. Agema, BC; Belderbos, BPS; Bins, S; de Wit, R; de With, M; El Bouazzaoui, S; Mathijssen, RHJ; Oomen-de Hoop, E; Singh, RK; van Schaik, RHN, 2020)	1.02
" The most common grade 3/4 adverse events were neutropenia (16."	( Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial. Hervonen, P; Huttunen, T; Jekunen, A; Kataja, V; Kautio, AL; Kellokumpu-Lehtinen, PL; Klintrup, K; Leskinen, M; Luukkaa, M; Marttila, T; Pulkkanen, K; Utriainen, T, 2020)	0.98
" To increase our understanding of the toxic effects of these treatments comprehensive MS-based proteomics were performed with HCT116, MDA-MB-231 and PC3 cells incubated with PACA-CBZ variants or free CBZ."	( Cabazitaxel-loaded poly(alkyl cyanoacrylate) nanoparticles: toxicity and changes in the proteome of breast, colon and prostate cancer cells. Iversen, TG; Mørch, Ý; Sandvig, K; Skotland, T; Sønstevold, T; Torgersen, ML; Øverbye, A, 2021)	2.06
" Regarding adverse events, within 8 months of treatment initiation, some kind of treatment for haematological toxicity was documented in 31% of patients given docetaxel and in 61% of patients given cabazitaxel."	( Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer. Glaeske, G; Horenkamp-Sonntag, D; Kreis, K; Schneider, U; Weissbach, L; Zeidler, J, 2022)	1.18
" Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 58% versus 49% of older patients receiving cabazitaxel versus abiraterone/enzalutamide and 48% versus 42% of younger patients."	( Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Poole, EM; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C, 2021)	1.15
"Chemotherapeutic agents can have both serious side effects and ototoxicity, which can be caused by direct toxic effects or by metabolic derangement by the agents."	( Cabazitaxel's ototoxicity: An animal study and histopathologic research. Bucak, A; Günebakan, Ç; Kahveci, OK; Kınar, A; Kuzu, S; Özdemir, Ç; Ulu, Ş, 2023)	2.35

Excerpt	Reference	Relevance
" The study also sought to determine the maximum tolerated dose and the recommended dose, to describe the pharmacokinetic (PK) behavior of the compound, and to seek preliminary evidence of anticancer activity."	( Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Beeram, M; Besenval, M; Debono, JS; Denis, LJ; Forouzesh, B; Goetz, AD; Mita, AC; Molpus, K; Ochoa, L; Patnaik, A; Rowinsky, EK; Semiond, D; Tolcher, AW, 2009)	0.35
" XRP6258 exhibited dose-proportional PK, a triphasic elimination profile, a long terminal half-life (77."	( Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Beeram, M; Besenval, M; Debono, JS; Denis, LJ; Forouzesh, B; Goetz, AD; Mita, AC; Molpus, K; Ochoa, L; Patnaik, A; Rowinsky, EK; Semiond, D; Tolcher, AW, 2009)	0.35
" Secondary objectives were to describe the safety profile, establish an appropriate dose, determine the pharmacokinetic (PK) profile of cabazitaxel, and assess antitumour activity."	( Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study. Assadourian, S; Delva, R; Diéras, V; Girre, V; Laurence, V; Livartowski, A; Lortholary, A; Pierga, JY; Semiond, D, 2013)	2.04
" Cabazitaxel demonstrated linear PK, a triphasic elimination profile, with a long half-life and high clearance."	( Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study. Assadourian, S; Delva, R; Diéras, V; Girre, V; Laurence, V; Livartowski, A; Lortholary, A; Pierga, JY; Semiond, D, 2013)	2.74
"To develop a population pharmacokinetic (PK) model for cabazitaxel in patients with advanced solid tumors and examine the influence of demographic and baseline parameters."	( Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors. Dai, Y; Ferron, GM; Semiond, D, 2013)	0.92
"The purpose of the study is to analyze the pharmacokinetic (PK) profile of cabazitaxel and evaluate its safety and tolerability as a 1-h IV infusion every 3 weeks in Japanese patients with castration-resistant prostate cancer (CRPC)."	( Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer. Miyazaki, J; Mukai, H; Nozawa, M; Ohno, K; Onozawa, Y; Suzuki, K; Takahashi, S, 2014)	0.87
"Cabazitaxel exhibited a triphasic elimination profile with a long terminal half-life of 116 ± 29."	( Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer. Miyazaki, J; Mukai, H; Nozawa, M; Ohno, K; Onozawa, Y; Suzuki, K; Takahashi, S, 2014)	2.08

Excerpt	Reference	Relevance
" Pharmacokinetic analysis showed no apparent drug-drug interaction."	( A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Awada, A; Besse, T; Campone, M; Dubin, F; Machiels, JP; Magherini, E; Pivot, X; Semiond, D; Villanueva, C, 2011)	0.64
"Cabazitaxel combined with capecitabine is active, has a safety profile consistent with a taxane plus capecitabine combination and warrants further investigation in patients with MBC."	( A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Awada, A; Besse, T; Campone, M; Dubin, F; Machiels, JP; Magherini, E; Pivot, X; Semiond, D; Villanueva, C, 2011)	2.08
" In both dose levels, cabazitaxel (4 cycles of cabazitaxel 25 mg/m + 2 cycles of cabazitaxel 20 mg/m in level 1, and 6 cycles of cabazitaxel 25 mg/m in level 2) were combined with 2 cycles of Re-HEDP 40 MBq/kg (1."	( A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial. Bloemendal, HJ; Bouman-Wammes, EW; de Klerk, JMH; van den Eertwegh, AJM; van Dodewaard-de Jong, JM; Verheul, HMW, 2017)	1.1
" We aimed to assess whether custirsen in combination with cabazitaxel and prednisone increases overall survival in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel."	( Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, ph Alekseev, B; Beer, TM; Blumenstein, B; Chi, KN; Fizazi, K; Fléchon, A; Gravis, G; Hotte, SJ; Jacobs, CA; Joly, F; Malik, Z; Matveev, V; Saad, F; Stewart, PS, 2017)	0.98

Excerpt	Reference	Relevance
" The biological agent cabozantinib, an orally bioavailable tyrosine kinase inhibitor with activity against Met and vascular endothelial growth factor receptor 2, demonstrated promising results in a phase II trial and is currently being assessed in two large randomized phase 3 controlled trials."	( The changing landscape in metastatic castration-resistant prostate cancer. Joshua, AM; Leibowitz-Amit, R, 2013)	0.39
" As expected, in the study of in vivo pharmacokinetics, the oral bioavailability of CTX was improved to 32."	( Entrapping of Nanoparticles in Yeast Cell Wall Microparticles for Macrophage-Targeted Oral Delivery of Cabazitaxel. Gou, J; He, H; Ren, T; Sun, W; Tan, X; Tang, X; Tao, X; Wang, P; Yin, T; Zhang, Y, 2018)	0.7
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" DLTs during subsequent cycles were mainly haematologic and reported at 25 and 30 mg/m(2) dosing levels."	( Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study. Assadourian, S; Delva, R; Diéras, V; Girre, V; Laurence, V; Livartowski, A; Lortholary, A; Pierga, JY; Semiond, D, 2013)	1.83
" Cabazitaxel showed linear pharmacokinetics and a terminal elimination half-life comparable with that of docetaxel, findings which support dosing as a single infusion in three-week treatment cycles."	( Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer? Figlin, R; Mita, AC; Mita, MM, 2012)	2.73
"Cbz at a dosage of 25mg/m(2) intravenously every 3 wk combined with 5mg of oral prednisone twice a day."	( Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Albers, P; Arsov, C; Bokemeyer, C; Ecstein-Fraisse, E; Gschwend, J; Heidenreich, A; Heinrich, E; Honecker, F; Keck, B; Miller, K; Müller, SC; Otremba, B; Pfister, D; Retz, M; Rogenhofer, S; Scholz, HJ; Steiner, U; Trojan, L; Volkmer, B; Wirth, M, 2013)	1.83
" This study evaluated a weekly cabazitaxel dosing regimen."	( Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours. Campone, M; Fumoleau, P; Gupta, S; Isambert, N; Sémiond, D; Trigo, JM, 2013)	0.96
" The observed safety profile and antitumour activity of cabazitaxel were consistent with those observed with other taxanes in similar dosing regimens."	( Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours. Campone, M; Fumoleau, P; Gupta, S; Isambert, N; Sémiond, D; Trigo, JM, 2013)	0.92
" Despite years of research, the optimal dosing regimen (weekly vs 3-weekly) and optimal dose is still controversial, as is the value of pharmacological personalization of taxane dosing."	( Metabolism of the taxanes including nab-paclitaxel. Joerger, M, 2015)	0.42
" The latter includes the ongoing debate on the most active and safe regimen (paclitaxel, docetaxel, nab-paclitaxel), the recommended initial dose (cabazitaxel) and pharmacological dosing individualization."	( Metabolism of the taxanes including nab-paclitaxel. Joerger, M, 2015)	0.62
" Still, the optimal dosing regimen (weekly vs 3 weekly) and optimal dose of the taxanes are controversial, as is the value of pharmacological personalization of taxane dosing."	( Treatment regimens of classical and newer taxanes. Joerger, M, 2016)	0.43
" Medication costs were calculated according to published pricing benchmarks factored by dosing and duration of therapy as stated in the prescribing information for each agent."	( Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer. Corman, S; Drea, E; Flannery, K; Gao, X; Hudspeth, L; Miao, R; Xue, M, 2017)	0.78
" The current dosing strategy of cabazitaxel is based on body surface area (BSA)."	( Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer. Bloemendal, HJ; Janssen, A; Mathijssen, RHJ; Ter Heine, R; van der Vlist, A; Verkleij, CPM, 2017)	0.97
"Ten patients with metastatic castration-resistant prostate cancer, who received cabazitaxel dosed on BSA as a part of routine palliative care, were enrolled in this study."	( Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer. Bloemendal, HJ; Janssen, A; Mathijssen, RHJ; Ter Heine, R; van der Vlist, A; Verkleij, CPM, 2017)	0.91
" The practical implication of our results might be to tailor cabazitaxel dosing on the basis of its hematological effects."	( Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel. Kosaka, T; Morita, S; Oya, M; Shinojima, T, 2018)	0.94
" As the flexible complex liposome, the dosage of cabazitaxel could be reduced to 25% that of the cabazitaxel injection while retaining a similar therapeutic effect."	( The Preparation, Determination of a Flexible Complex Liposome Co-Loaded with Cabazitaxel and β-Elemene, and Animal Pharmacodynamics on Paclitaxel-Resistant Lung Adenocarcinoma. Li, CX; Xie, T; Zeng, YJ; Zeng, YY; Zeng, ZW; Zhang, NN, 2019)	1
" The patient developed grade 4 thrombocytopenia during the first 4 cycles, and the dosage of cabazitaxel had to be tapered to 12."	( Long-Term Prostate-Specific Antigen Response on a Low-Dose Cabazitaxel Regimen for Metastatic Castration-Resistant Prostate Cancer: A Case Report. Ikari, R; Kageyama, S; Kawauchi, A; Kubota, S; Nagasawa, M; Narita, M; Tomita, K; Wada, A; Yoshida, T, 2021)	1.08
"Pharmacokinetic-guided dosing of cabazitaxel in patients with mCRPC is feasible and improves clinical outcome due to individual dose escalations in 55% of patients."	( Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer. Boegemann, M; Buck, SAJ; Cathomas, R; Feyerabend, S; Gillessen, S; Heidenreich, A; Jaehde, U; Joerger, M; Larcher-Senn, J; Loidl, W; Lorch, A; Mathijssen, RHJ; Omlin, A; Reuter, C; Tsaur, I; von Amsberg, G, 2023)	1.52
"Overview of the existing literature regarding approval, dosage and new combination options for metastatic castration-resistant prostate cancer (mCRPC)."	( [Role of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) treatment: still standard or exception?] Thomas, C, 2023)	0.91
" Therapy adherence for taxanes can be significantly improved by dosage adjustments."	( [Role of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) treatment: still standard or exception?] Thomas, C, 2023)	0.91

Role	Description
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
microtubule-stabilising agent	Any substance that interacts with tubulin to promote polymerisation of microtubules.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
tetracyclic diterpenoid	A diterpenoid with a tetracyclic skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Fumarate hydratase	Homo sapiens (human)	Potency	5.2576	0.0030	8.7949	48.0869	AID1347053
PPM1D protein	Homo sapiens (human)	Potency	0.0033	0.0052	9.4661	32.9993	AID1347411
EWS/FLI fusion protein	Homo sapiens (human)	Potency	0.2396	0.0013	10.1577	42.8575	AID1259253; AID1259256
polyprotein	Zika virus	Potency	5.2576	0.0030	8.7949	48.0869	AID1347053
Interferon beta	Homo sapiens (human)	Potency	0.0033	0.0033	9.1582	39.8107	AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (86)

Assay ID	Title	Year	Journal	Article
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1765197	Cell cycle arrest in human A549 cells assessed as accumulation at G1 phase at 40 nM measured after 24 hrs by propidium iodide/RNase A staining based flowcytometry analysis (Rvb = 58%)	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	Synthesis and biological evaluation of novel cabazitaxel analogues.
AID1068916	Growth inhibition of human BGC823 cells by MTT assay	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Biological evaluation of new antitumor taxoids: alteration of substitution at the C-7 and C-10 of docetaxel.
AID1068924	Growth inhibition of human HeLa cells by MTT assay	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Biological evaluation of new antitumor taxoids: alteration of substitution at the C-7 and C-10 of docetaxel.
AID1068917	Growth inhibition of human K562 cells by MTT assay	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Biological evaluation of new antitumor taxoids: alteration of substitution at the C-7 and C-10 of docetaxel.
AID1061916	Cytotoxicity against human NCI-H460 cells at 1 uM after 72 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	The synthesis of novel taxoids for oral administration.
AID1068915	Growth inhibition of human PANC1 cells by MTT assay	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Biological evaluation of new antitumor taxoids: alteration of substitution at the C-7 and C-10 of docetaxel.
AID1454746	Cytotoxicity against human A549 cells	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID1765196	Resistance index, ratio of IC50 for human A549/Taxol cells to IC50 for human A549 cells	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	Synthesis and biological evaluation of novel cabazitaxel analogues.
AID1765198	Cytotoxicity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	Synthesis and biological evaluation of novel cabazitaxel analogues.
AID1061914	Cytotoxicity against human A375 cells at 1 uM after 72 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	The synthesis of novel taxoids for oral administration.
AID1068927	Growth inhibition of human A549 cells by MTT assay	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Biological evaluation of new antitumor taxoids: alteration of substitution at the C-7 and C-10 of docetaxel.
AID1765202	Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 40 nM measured after 24 hrs by propidium iodide/RNase A staining based flowcytometry analysis (Rvb = 28.6%)	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	Synthesis and biological evaluation of novel cabazitaxel analogues.
AID1068920	Growth inhibition of human U937 cells by MTT assay	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Biological evaluation of new antitumor taxoids: alteration of substitution at the C-7 and C-10 of docetaxel.
AID1765200	Resistance index, ratio of IC50 for human KB/VCR cells to IC50 for human KB cells	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	Synthesis and biological evaluation of novel cabazitaxel analogues.
AID1765203	Antitumour activity against human A549 cells xenografted in SCID mouse assessed as tumour growth inhibition at 5 mg/kg, iv administered twice a week for 15 days by caliper method relative to control	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	Synthesis and biological evaluation of novel cabazitaxel analogues.
AID1061913	Cytotoxicity against human HT-29 cells at 1 uM after 72 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	The synthesis of novel taxoids for oral administration.
AID1765195	Cytotoxicity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	Synthesis and biological evaluation of novel cabazitaxel analogues.
AID1638694	Cytotoxicity in human NCI-H524 cells pre-incubated for 2 hrs followed by compound wash out and subsequently incubated for 70 hrs by Cell Titer Glo assay	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo.
AID1388651	Growth inhibition of human MES-SA/Dx5 cells after 72 hrs by SRB assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment.
AID1068921	Growth inhibition of human MCF7 cells by MTT assay	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Biological evaluation of new antitumor taxoids: alteration of substitution at the C-7 and C-10 of docetaxel.
AID1068925	Growth inhibition of human HL60 cells by MTT assay	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Biological evaluation of new antitumor taxoids: alteration of substitution at the C-7 and C-10 of docetaxel.
AID1068919	Growth inhibition of human SGC7901 cells by MTT assay	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Biological evaluation of new antitumor taxoids: alteration of substitution at the C-7 and C-10 of docetaxel.
AID1061915	Cytotoxicity against human MCF7 cells at 1 uM after 72 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	The synthesis of novel taxoids for oral administration.
AID1061917	Cytotoxicity against human HeLa cells at 1 uM after 72 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	The synthesis of novel taxoids for oral administration.
AID1765201	Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 40 nM measured after 24 hrs by propidium iodide/RNase A staining based flowcytometry analysis (Rvb = 13.4%)	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	Synthesis and biological evaluation of novel cabazitaxel analogues.
AID1061909	Apparent permeability from apical to basolateral side in human Caco2 cells at 10 uM after 90 mins by LC-MS/MS analysis	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	The synthesis of novel taxoids for oral administration.
AID1061912	Cytotoxicity against human DU145 cells at 1 uM after 72 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	The synthesis of novel taxoids for oral administration.
AID1765199	Cytotoxicity against human KB/VCR cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	Synthesis and biological evaluation of novel cabazitaxel analogues.
AID1061918	Cytotoxicity against human A2780 cells at 1 uM after 72 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	The synthesis of novel taxoids for oral administration.
AID1068922	Growth inhibition of human DU145 cells by MTT assay	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Biological evaluation of new antitumor taxoids: alteration of substitution at the C-7 and C-10 of docetaxel.
AID1068923	Growth inhibition of human A431 cells by MTT assay	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Biological evaluation of new antitumor taxoids: alteration of substitution at the C-7 and C-10 of docetaxel.
AID1061911	Cytotoxicity against human HL60 cells at 1 uM after 72 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	The synthesis of novel taxoids for oral administration.
AID1765194	Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	Synthesis and biological evaluation of novel cabazitaxel analogues.
AID1068928	Growth inhibition of human HT1080 cells by MTT assay	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Biological evaluation of new antitumor taxoids: alteration of substitution at the C-7 and C-10 of docetaxel.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347414	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (0.52)	29.6817
2010's	413 (70.96)	24.3611
2020's	166 (28.52)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	79 (13.14%)	5.53%
Reviews	130 (21.63%)	6.00%
Case Studies	21 (3.49%)	4.05%
Observational	12 (2.00%)	0.25%
Other	359 (59.73%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
choline [no description available]	2.11	1	0	cholines	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter; nutrient; plant metabolite; Saccharomyces cerevisiae metabolite
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	3.18	1	0	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	2.15	1	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
glycerol Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.	2.1	1	0	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
iodine Iodine: A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.. diiodine : Molecule comprising two covalently bonded iodine atoms with overall zero charge..	2.17	1	0	diatomic iodine	nutrient
buspirone Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.. buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.	3.27	1	0	azaspiro compound; N-alkylpiperazine; N-arylpiperazine; organic heteropolycyclic compound; piperidones; pyrimidines	anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	3.27	1	0	aromatic ether; nitrile; polyether; tertiary amino compound
disulfiram [no description available]	2.11	1	0	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
etidronate Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.	3.94	2	1	1,1-bis(phosphonic acid)	antineoplastic agent; bone density conservation agent; chelator
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	4.84	2	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	10.27	3	1	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.66	2	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	2.15	1	0	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
mitotane Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.	4.72	1	1	diarylmethane
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	15.02	35	17	dihydroxyanthraquinone	analgesic; antineoplastic agent
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	2.13	1	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	12.5	8	1	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	15.79	44	22	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	5.27	3	1	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
phenylethyl alcohol Phenylethyl Alcohol: An antimicrobial, antiseptic, and disinfectant that is used also as an aromatic essence and preservative in pharmaceutics and perfumery.. 2-phenylethanol : A primary alcohol that is ethanol substituted by a phenyl group at position 2.	2.25	1	0	benzenes; primary alcohol	Aspergillus metabolite; fragrance; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite
cytarabine [no description available]	2.21	1	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
acrylic acid acrylic acid: RN given refers to parent cpd. acrylic acid : A alpha,beta-unsaturated monocarboxylic acid that is ethene substituted by a carboxy group.	2.15	1	0	alpha,beta-unsaturated monocarboxylic acid	metabolite
methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.	2.21	1	0	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	5.46	2	0	pyrrole; secondary amine
citronellol citronellol: alcohol form of citronellal; found in rose oil; RN given refers to parent cpd without isomeric designation; structure. citronellol : A monoterpenoid that is oct-6-ene substituted by a hydroxy group at position 1 and methyl groups at positions 3 and 7.. insect repellent : An insecticide that acts as a repellent to insects.	7.13	1	0	monoterpenoid	plant metabolite
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.31	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
thiazoles [no description available]	6.57	4	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	2.13	1	0	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
thymoquinone thymoquinone: constituent of cedarwood; can cause dermatitis; structure. thymoquinone : A member of the class of 1,4-benzoquinones that is 1,4-bezoquinone in which the hydrogens at positions 2 and 5 are replaced by methyl and isopropyl groups, respectively. It is a natural compound isolated from Nigella sativa which has demonstrated promising chemotherapeutic activity.	7.21	1	0	1,4-benzoquinones	adjuvant; anti-inflammatory agent; antidepressant; antineoplastic agent; antioxidant; cardioprotective agent; plant metabolite
caprolactone hexano-6-lactone : A epsilon-lactone that is oxepane substituted by an oxo group at position 2.	7.15	1	0	epsilon-lactone
elemene elemene: a sclerosing and antineoplastic agent isolated from Curcuma wenyujin & Rhizoma zedoariae; beta- and delta- elemene are also available	7.31	1	0
hesperidin Hesperidin: A flavanone glycoside found in CITRUS fruit peels.. hesperidin : A disaccharide derivative that consists of hesperetin substituted by a 6-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.	2.17	1	0	3'-hydroxyflavanones; 4'-methoxyflavanones; dihydroxyflavanone; disaccharide derivative; flavanone glycoside; monomethoxyflavanone; rutinoside	mutagen
dihydrotestosterone Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.	2.25	1	0	17beta-hydroxy steroid; 17beta-hydroxyandrostan-3-one; 3-oxo-5alpha-steroid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
3-hydroxyflavone 3-hydroxyflavone: structure given in first source. flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone.	2.13	1	0	flavonols; monohydroxyflavone
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	2.1	1	0	cyclic ketone; erythromycin
deoxycytidine [no description available]	6.47	5	3	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
d-alpha tocopherol Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.	2.41	1	0	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
pimozide Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403). pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group.	2.6	1	0	benzimidazoles; heteroarylpiperidine; organofluorine compound	antidyskinesia agent; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
lutetium Lutetium: An element of the rare earth family of metals. It has the atomic symbol Lu, atomic number 71, and atomic weight 175.	2.72	2	0	d-block element atom; lanthanoid atom
gadolinium Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.	2.15	1	0	f-block element atom; lanthanoid atom
transferrin Transferrin: An iron-binding beta1-globulin that is synthesized in the LIVER and secreted into the blood. It plays a central role in the transport of IRON throughout the circulation. A variety of transferrin isoforms exist in humans, including some that are considered markers for specific disease states.	2.31	1	0
azides Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.	2.17	1	0	pseudohalide anion	mitochondrial respiratory-chain inhibitor
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	9.92	22	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	3.65	2	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
lovastatin Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).	3.27	1	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	3.27	1	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
gepirone gepirone: RN given refers to parent cpd; structure given in first source	3.27	1	0	N-arylpiperazine
itraconazole Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.	2.13	1	0	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	10.88	2	2	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	5.05	4	2	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
capecitabine Capecitabine: A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.. capecitabine : A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.	9.37	1	1	carbamate ester; cytidines; organofluorine compound	antimetabolite; antineoplastic agent; prodrug
betulinic acid [no description available]	3.27	1	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite
calanolide a calanolide A: NSC 661122 and costatolide are isomers; a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum (Clusiaceae); structure in first source. (+)-calanolide A : An organic heterotetracyclic compound that is 11,12-dihydro-2H,6H,10H-dipyrano[2,3-f:2',3'-h]chromen-2-one substituted by a hydroxy group at position 12, methyl groups at positions 6, 6, 10 and 11 and a propyl group at position 4 (the 10R,11S,12S stereoisomer). Isolated from Calophyllum lanigerum var austrocoriaceum and Calophyllum brasiliense, it exhibits potent activity against HIV-1 reverse transcriptase.	3.27	1	0	cyclic ether; delta-lactone; organic heterotetracyclic compound; secondary alcohol	HIV-1 reverse transcriptase inhibitor; plant metabolite
lissamine rhodamine b lissamine rhodamine B: RN given refers to parent cpd; Lissamine Rhodamine B refers to Na salt	2.11	1	0
fluorodeoxyglucose f18 Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)	4.9	2	1	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	6.46	6	0	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
tocophersolan tocophersolan: RN given refers to parent cpd	2.41	1	0	tocol
hesperetin [no description available]	2.17	1	0	3'-hydroxyflavanones; 4'-methoxyflavanones; monomethoxyflavanone; trihydroxyflavanone	antineoplastic agent; antioxidant; plant metabolite
suksdorfin suksdorfin: from the fruit of Lomatium sukdorfi; structure given in first source	3.27	1	0
bexarotene [no description available]	3.27	1	0	benzoic acids; naphthalenes; retinoid	antineoplastic agent
equol Equol: A non-steroidal ESTROGEN generated when soybean products are metabolized by certain bacteria in the intestines.	2.21	1	0	hydroxyisoflavans
mci 9038 [no description available]	3.27	1	0	peptide
rhenium-186 hedp rhenium-186 HEDP: used as a complement to analgesic therapy in patients with painful disseminated bone metastases	3.94	2	1
abiraterone [no description available]	17.55	105	13	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; pyridines	antineoplastic agent; EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	20.46	251	37	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
tariquidar [no description available]	3.27	1	0	benzamides
atrasentan Atrasentan: A pyrrolidine and benzodioxole derivative that acts a RECEPTOR, ENDOTHELIN A antagonist. It has therapeutic potential as an antineoplastic agent and for the treatment of DIABETIC NEPHROPATHIES.	5.46	2	0	pyrrolidines
pyropheophorbide a pyropheophorbide a: RN given refers to (3S-trans)-isomer	2.17	1	0
2'-hydroxyflavanone [no description available]	2.31	1	0
estramustine Estramustine: A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.. estramustine : A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.	9.79	5	0	17beta-hydroxy steroid; carbamate ester; organochlorine compound	alkylating agent; antineoplastic agent; radiation protective agent
homoharringtonine Homoharringtonine: Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC.. omacetaxine mepesuccinate : A cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia.	3.27	1	0	alkaloid ester; enol ether; organic heteropentacyclic compound; tertiary alcohol	anticoronaviral agent; antineoplastic agent; apoptosis inducer; protein synthesis inhibitor
n,n-dimethyl-n-(18f)fluoromethyl-2-hydroxyethylammonium [no description available]	2.11	1	0
carboplatin [no description available]	4.87	6	1
epiglucan epiglucan: a highly side-chain/branched alkali-insoluble cell wall glucan from fungus such as Epicoccum nigrum, Botrytis cinerea, ascomycetes & basidiomycetes; also isolated S-4001 from Lei Wan (polyporus mylitiae), HA-beta-glucan from mushroom Pleutotus ostreatus (Fr.) Quel., and translam from seaweed Laminaria cichorioides; with commercially important functional properties including emulsification and friction reduction.	2.17	1	0
cromakalim [no description available]	3.27	1	0	1-benzopyran
betadex beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.	2.21	1	0	cyclodextrin
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	2.13	1	0	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	2.17	1	0	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
oleic acid Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.	2.17	1	0	octadec-9-enoic acid	antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent
epothilone b [no description available]	3.27	1	0	epothilone; epoxide	antineoplastic agent; apoptosis inducer; microtubule-stabilising agent
epothilone a Epothilones: A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).	3.17	1	0	epothilone; epoxide	antineoplastic agent; metabolite; microtubule-stabilising agent; tubulin modulator
bevirimat bevirimat: an HIV inhibitor; disrupts late step in processing HIV Major Core Protein p24, preventing the capsid precursor p25 from being converted to mature capsid p24. bevirimat : A pentacyclic triterpenoid obtained by the formal condensation of 2,2-dimethylsuccinic acid with the 3-hydroxy group of betulinic acid. It is isolated from the Chinese herb Syzygium claviflorum. The first in the class of HIV-1 maturation inhibitors to be studied in humans, bevirimat was identified as a potent HIV drug candidate and several clinical trials were conducted, but development into a new drug was plagued by numerous resistance-related problems.	3.27	1	0	dicarboxylic acid monoester; monocarboxylic acid; pentacyclic triterpenoid	HIV-1 maturation inhibitor; metabolite
piplartine piplartine: Antineoplastic Agent, Phytogenic; alkaloid from Piper; structure in first source	2.17	1	0	cinnamamides; dicarboximide
leuprolide Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	10.45	3	1	oligopeptide	anti-estrogen; antineoplastic agent; gonadotropin releasing hormone agonist
sesquiterpenes [no description available]	2.66	2	0
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	7.25	1	0	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
thiohydantoins Thiohydantoins: Sulfur analogs of hydantoins with one or both carbonyl groups replaced by thiocarbonyl groups.	3.31	1	0
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	2.1	1	0	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
orlistat Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.	7.31	1	0	beta-lactone; carboxylic ester; formamides; L-leucine derivative	anti-obesity agent; bacterial metabolite; EC 2.3.1.85 (fatty acid synthase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor
ly335979 [no description available]	3.27	1	0	carbopolycyclic compound
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	7.13	6	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
salinomycin salinomycin: from Streptomyces albus; RN given refers to parent cpd; structure	2.9	2	0	polyketide; spiroketal	animal growth promotant; potassium ionophore
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	2.25	1	0
genistein [no description available]	7.53	2	0	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
fisetin [no description available]	7.13	1	0	3'-hydroxyflavonoid; 7-hydroxyflavonol; tetrahydroxyflavone	anti-inflammatory agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; metabolite; plant metabolite
daidzein [no description available]	2.21	1	0	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite
caffeic acid phenethyl ester phenethyl caffeate : An alkyl caffeate ester in which 2-phenylethyl is the alkyl component.	2.25	1	0	alkyl caffeate ester	anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; antiviral agent; immunomodulator; metabolite; neuroprotective agent
sdz psc 833 valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215	2.11	1	0	homodetic cyclic peptide
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	2.17	1	0	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
goserelin Goserelin: A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.	2.1	1	0	organic molecular entity
su 11248 [no description available]	5.46	2	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
strontium Strontium: An element of the alkaline earth family of metals. It has the atomic symbol Sr, atomic number 38, and atomic weight 87.62.	3.18	1	0	alkaline earth metal atom
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	7.15	1	0	cysteinium	fundamental metabolite
strontium radioisotopes Strontium Radioisotopes: Unstable isotopes of strontium that decay or disintegrate spontaneously emitting radiation. Sr 80-83, 85, and 89-95 are radioactive strontium isotopes.	3.18	1	0
radium Radium: A radioactive element of the alkaline earth series of metals. It has the atomic symbol Ra and atomic number 88. Radium is the product of the disintegration of URANIUM and is present in pitchblende and all ores containing uranium. It is used clinically as a source of beta and gamma-rays in radiotherapy, particularly BRACHYTHERAPY.	10.49	31	0	alkaline earth metal atom
ixabepilone [no description available]	4.77	3	0	1,3-thiazoles; beta-hydroxy ketone; epoxide; lactam; macrocycle	antineoplastic agent; microtubule-destabilising agent
tubacin tubacin: inhibits histone deacetylase 6; structure in first source	2.13	1	0	1,3-oxazoles
beta-elemene beta-elemene: increases tumor cell immunogenicity by inducing, at least in part, elevated expression of heat shock protein 70 on tumor cell surface. beta-elemene : A sesquiterpene that consists of cyclohexane bearing methyl and vinyl substituents at position 1 as well as two isopropenyl substituents at positions 2 and 4.. (-)-beta-elemene : The (-)-enantiomer of beta-elemene that has (1S,2S,4R)-configuration.	2.21	1	0	beta-elemene	antineoplastic agent
idn 5109 IDN 5109: structure in first source	2.1	1	0
taxane taxane: produced by Taxomyces andreanae	9.06	13	2	diterpene; terpenoid fundamental parent
orteronel orteronel: non-steroidal 17,20-lyase inhibitor; structure in first source	3.6	2	0
abiraterone acetate Abiraterone Acetate: An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.. abiraterone acetate : A sterol ester obtained by formal condensation of the 3-hydroxy group of abiraterone with the carboxy group of acetic acid. A prodrug that is converted in vivo into abiraterone. Used for treatment of metastatic castrate-resistant prostate cancer.	13.67	40	5	pyridines; sterol ester	antineoplastic agent; EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor; prodrug
zibotentan ZD4054: a potent endothelin receptor A antagonist that inhibits ovarian carcinoma cell proliferation	2.07	1	0	phenylpyridine
sepantronium sepantronium: a survivin suppressant with antineoplastic activity. sepantronium : An organic cation that is 1-(2-methoxyethyl)-2-methyl-1H-naphtho[2,3-d]imidazole-4,9-dione in which the nitrogen at position 3 of the napthoimidazole moiety has been alkylated by a pyrazin-2-ylmethyl group.	2.25	1	0	organic cation
arisugacin arisugacin: isolated from Penicillium sp. FO-4259; structure given in first source. arisugacin A : An organic heterotetracyclic compound that is 4a,12a-dihydroxy-4,4,6a,12b-tetramethyl-4a,6,6a,12,12a,12b-hexahydro-4H,11H-benzo[f]pyrano[4,3-b]chromene-1,11(5H)-dione substituted by 3,4-dimethoxyphenyl group at position 9 (the 4aR,6aR,12aS,12bS steroisomer). Isolated from the culture broth of Penicillium, it acts as a selective inhibitor of acetylcholinesterase.	3.27	1	0	aromatic ether; delta-lactone; enone; organic heterotetracyclic compound; tertiary alcohol	antimicrobial agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; metabolite; Penicillium metabolite
vinflunine vinflunine: inhibits tubulin assembly; structure in first source. vinflunine : An organic heteropentacyclic compound and an organic heterotetracyclic compound that is vinorelbine in which the tetrahydropyridine moiety of the heterotetracyclic part of the molecule has been redced to the corresponding piperidine, and in which the ethyl group attached to this ring has been replaced by a 1,1-difluoroethyl group.	9.45	1	1	acetate ester; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; semisynthetic derivative; vinca alkaloid	antineoplastic agent
nu 7441 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one: structure in first source	2.31	1	0	dibenzothiophenes
nvp-aew541 [no description available]	3.27	1	0
monomethyl auristatin e [no description available]	2.21	1	0
indocyanine green Indocyanine Green: A tricarbocyanine dye that is used diagnostically in liver function tests and to determine blood volume and cardiac output.	7.15	1	0	1,1-diunsubstituted alkanesulfonate; benzoindole; cyanine dye
mdv 3100 [no description available]	17.48	108	11	(trifluoromethyl)benzenes; benzamides; imidazolidinone; monofluorobenzenes; nitrile; thiocarbonyl compound	androgen antagonist; antineoplastic agent
prosomatostatin [no description available]	2.21	1	0	heterodetic cyclic peptide; peptide hormone	fungal metabolite; mouse metabolite; rat metabolite
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide: FE-200486 is the acetate salt	3.59	2	0	polypeptide
endothelin-1 Endothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)	5.46	2	0
phosphatidylcholines Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.	2.1	1	0	1,2-diacyl-sn-glycero-3-phosphocholine
chlorophyll a Chlorophyll: Porphyrin derivatives containing magnesium that act to convert light energy in photosynthetic organisms.. chlorophyll : A family of magnesium porphyrins, defined by the presence of a fifth ring beyond the four pyrrole-like rings. The rings can have various side chains which usually include a long phytol chain.	2.17	1	0	chlorophyll; methyl ester	cofactor
chitosan [no description available]	7.76	2	0
apalutamide [no description available]	3.31	1	0
cabozantinib cabozantinib: a multikinase inhibitor. cabozantinib : A dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer.	7.12	6	0	aromatic ether; dicarboxylic acid diamide; organofluorine compound; quinolines	antineoplastic agent; tyrosine kinase inhibitor
glycolipids [no description available]	2.1	1	0
scyx 7158 [no description available]	3.27	1	0	(trifluoromethyl)benzenes
piperidines Piperidines: A family of hexahydropyridines.	2.17	1	0
novobiocin Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.	3.27	1	0	carbamate ester; ether; hexoside; hydroxycoumarin; monocarboxylic acid amide; monosaccharide derivative; phenols	antibacterial agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Escherichia coli metabolite; hepatoprotective agent
tasquinimod tasquinimod: a lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer; structure in first source	10.27	3	1
clorobiocin clorobiocin: chlorine-containing antibiotic related to novobiocin	3.27	1	0
psma-617 PSMA-617: inhibits prostate-specific membrane antigen; structure in first source	5.67	4	1
orabase Orabase: used in therapy of oral mucosal ulcers	2.85	3	0
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	7.91	3	0	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	8.48	1	1	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	8.48	1	1	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist

Condition	Indicated	Relationship Strength	Studies	Trials
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	3.95	11	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Experimental Neoplasms [description not available]	0	3.25	5	0
Colorectal Cancer [description not available]	0	7.31	1	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	1	4.31	1	0
Glial Cell Tumors [description not available]	0	2.93	3	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	1	9.93	3	0
Androgen-Independent Prostatic Cancer [description not available]	0	20.58	284	49
Prostatic Neoplasms, Castration-Resistant Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.	0	20.58	284	49
Osteogenic Sarcoma [description not available]	0	2.76	2	0
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	0	2.76	2	0
Cancer of Prostate [description not available]	0	22.87	301	127
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	1	30.4	1,204	508
Metastase [description not available]	0	16.92	86	23
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	16.92	86	23
Cancer of Lung [description not available]	0	8.15	14	4
Lung Neoplasms Tumors or cancer of the LUNG.	0	8.15	14	4
Cells, Neoplasm Circulating [description not available]	0	10.55	18	5
Recrudescence [description not available]	0	5.08	4	2
Bone Cancer [description not available]	0	8.96	33	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	0	8.96	33	0
Disease Exacerbation [description not available]	0	21.16	165	128
Adrenocortical Carcinoma A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.	0	4.99	2	1
Adrenal Cortex Cancer [description not available]	0	4.99	2	1
Adrenal Cortex Neoplasms Tumors or cancers of the ADRENAL CORTEX.	1	6.99	2	1
Benign Neoplasms, Brain [description not available]	0	4.67	9	0
Astrocytoma, Grade IV [description not available]	0	2.93	3	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	1	6.67	9	0
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	1	4.93	3	0
Cancer of Liver [description not available]	0	5.98	8	1
Liver Neoplasms Tumors or cancer of the LIVER.	0	5.98	8	1
Febrile Neutropenia Fever accompanied by a significant reduction in the number of NEUTROPHILS.	0	7.96	3	0
Benign Neoplasms [description not available]	0	12.02	28	8
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1	16.61	56	16
Sarcopenia Progressive decline in muscle mass due to aging which results in decreased functional capacity of muscles.	0	7.41	1	0
Atypical Lipomatous Tumor [description not available]	0	2.41	1	0
Sarcoma, Epithelioid [description not available]	0	3.98	2	1
Liposarcoma A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)	1	9.41	1	0
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	0	8.98	2	1
Soft Tissue Neoplasms Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.	0	3.98	2	1
Cancer of Head [description not available]	0	3.92	2	1
Local Neoplasm Recurrence [description not available]	0	10.96	17	5
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	1	5.92	2	1
Peritoneal Carcinomatosis [description not available]	0	2.9	2	0
Peritoneal Neoplasms Tumors or cancer of the PERITONEUM.	0	2.9	2	0
Thrombopenia [description not available]	0	4.52	4	1
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	0	4.52	4	1
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	0	19.77	140	125
Drug-Induced Cochlear Toxicity [description not available]	0	2.6	1	0
Ototoxicity Damage to the EAR or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.	0	7.6	1	0
Blood Pressure, High [description not available]	0	2.6	1	0
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	0	2.6	1	0
Carcinoma, Anaplastic [description not available]	0	4.45	4	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	0	4.45	4	0
Atypical Ductal Hyperplasia [description not available]	0	2.6	1	0
Hematuria Presence of blood in the urine.	0	3.09	4	0
Carcinoma, Intraductal, Noninfiltrating A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.	0	2.6	1	0
Cancer of Penis [description not available]	0	3.97	2	1
Penile Neoplasms Cancers or tumors of the PENIS or of its component tissues.	1	5.97	2	1
Cancer, Second Primary [description not available]	0	2.88	3	0
B16 Melanoma [description not available]	0	2.53	2	0
Lymph Node Metastasis [description not available]	0	3.27	5	0
Cancer of Mediastinum [description not available]	0	2.25	1	0
Cancer, Embryonal [description not available]	0	3.77	3	0
Cancer of Testis [description not available]	0	4.43	4	0
Mediastinal Neoplasms Tumors or cancer of the MEDIASTINUM.	0	2.25	1	0
Neoplasms, Germ Cell and Embryonal Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.	0	3.77	3	0
Retroperitoneal Neoplasms New abnormal growth of tissue in the RETROPERITONEAL SPACE.	0	2.25	1	0
Testicular Neoplasms Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.	1	6.43	4	0
Cancer of Cervix [description not available]	0	2.25	1	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	0	2.25	1	0
Latent Tuberculosis The dormant form of TUBERCULOSIS where the person shows no obvious symptoms and no sign of the causative agent (Mycobacterium tuberculosis) in the SPUTUM despite being positive for tuberculosis infection skin test.	0	7.21	1	0
Tuberculosis, Miliary An acute form of TUBERCULOSIS in which minute tubercles are formed in a number of organs of the body due to dissemination of the bacilli through the blood stream.	0	2.21	1	0
Leukocytopenia [description not available]	0	5.9	2	1
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	0	5.9	2	1
Bladder Cancer [description not available]	0	6.59	4	4
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	1	10.3	8	8
Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.	1	8.59	4	4
Ache [description not available]	0	6.25	6	2
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	0	6.25	6	2
Genome Instability [description not available]	0	4.92	2	1
Cancer of Pancreas [description not available]	0	3.95	2	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	0	3.95	2	1
Breast Cancer [description not available]	0	10.86	19	7
Breast Neoplasms Tumors or cancer of the human BREAST.	1	12.86	19	7
Adenocarcinoma, Basal Cell [description not available]	0	11.29	26	7
Cancer of Esophagus [description not available]	0	5.16	3	3
Cancer of Stomach [description not available]	0	5.16	3	3
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	16.29	26	7
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	0	5.16	3	3
Stomach Neoplasms Tumors or cancer of the STOMACH.	1	7.16	3	3
Response Evaluation Criteria in Solid Tumors An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.	0	7.33	4	4
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	0	5.22	3	1
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	0	5.22	3	1
Cancer of Ovary [description not available]	0	3.64	1	1
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	1	5.64	1	1
Carcinoma, Lewis Lung A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.	0	2.58	2	0
Acute Confusional Senile Dementia [description not available]	0	2.25	1	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	0	2.25	1	0
Malignant Melanoma [description not available]	0	2.72	2	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	0	2.72	2	0
Adverse Drug Event [description not available]	0	4.14	5	0
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	4.14	5	0
Chemotherapy-Induced Febrile Neutropenia FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.	0	2.17	1	0
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	0	3.22	5	0
Asthenia Clinical sign or symptom manifested as debility, or lack or loss of strength and energy.	0	2.59	2	0
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	0	2.81	3	0
Bilateral Headache [description not available]	0	2.15	1	0
Headache The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.	0	7.15	1	0
Experimental Mammary Neoplasms [description not available]	0	2.15	1	0
Pelvic Pain Pain in the pelvic region of genital and non-genital origin.	0	7.15	1	0
Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.	0	3.06	1	0
Lassitude [description not available]	0	5.8	4	1
Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.	0	5.8	4	1
Invasiveness, Neoplasm [description not available]	0	7.05	6	1
Animal Mammary Carcinoma [description not available]	0	2.57	2	0
Leukemia, Pre-B-Cell [description not available]	0	2.17	1	0
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.	0	2.17	1	0
Optic Atrophy Atrophy of the optic disk which may be congenital or acquired. This condition indicates a deficiency in the number of nerve fibers which arise in the RETINA and converge to form the OPTIC DISK; OPTIC NERVE; OPTIC CHIASM; and optic tracts. GLAUCOMA; ISCHEMIA; inflammation, a chronic elevation of intracranial pressure, toxins, optic nerve compression, and inherited conditions (see OPTIC ATROPHIES, HEREDITARY) are relatively common causes of this condition.	0	7.21	1	0
Carcinoma, Small Cell Lung [description not available]	0	5.88	2	2
Small Cell Lung Carcinoma A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).	1	7.88	2	2
Extravascular Hemolysis [description not available]	0	2.21	1	0
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	0	2.21	1	0
Lung Adenocarcinoma [description not available]	0	7.87	3	0
Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.	0	2.87	3	0
Experimental Leukemia [description not available]	0	2.21	1	0
Acute Myelogenous Leukemia [description not available]	0	2.21	1	0
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	0	2.21	1	0
Adenocarcinoma Of Kidney [description not available]	0	2.55	2	0
Cancer of Kidney [description not available]	0	2.21	1	0
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	0	2.55	2	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	0	2.21	1	0
Diffuse Parenchymal Lung Disease [description not available]	0	2.21	1	0
Breathlessness [description not available]	0	3.95	2	1
Dyspnea Difficult or labored breathing.	0	3.95	2	1
Lung Diseases, Interstitial A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.	0	2.21	1	0
Hormone-Dependent Neoplasms [description not available]	0	6.17	11	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	3.87	2	1
Peripheral Nerve Diseases [description not available]	0	4.8	2	1
Peripheral Nervous System Diseases Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.	0	4.8	2	1
Age-Related Osteoporosis [description not available]	0	3	1	0
Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	0	3	1	0
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	0	2.1	1	0
Injuries, Radiation [description not available]	0	2.1	1	0
Cystitis Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.	0	2.51	2	0
Drug Overdose Accidental or deliberate use of a medication or street drug in excess of normal dosage.	0	2.1	1	0
Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.	0	2.1	1	0
Neuroectodermal Tumors Malignant neoplasms arising in the neuroectoderm, the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems, including some glial cells.	0	2.11	1	0
Arachnoidal Cerebellar Sarcoma, Circumscribed [description not available]	0	2.11	1	0
Dysembryoma [description not available]	0	2.11	1	0
Medulloblastoma A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)	0	2.11	1	0
Teratoma A true neoplasm composed of a number of different types of tissue, none of which is native to the area in which it occurs. It is composed of tissues that are derived from three germinal layers, the endoderm, mesoderm, and ectoderm. They are classified histologically as mature (benign) or immature (malignant). (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1642)	0	2.11	1	0
Rhabdoid Tumor A rare but highly lethal childhood tumor found almost exclusively in infants. Histopathologically, it resembles RHABDOMYOSARCOMA but the tumor cells are not of myogenic origin. Although it arises primarily in the kidney, it may be found in other parts of the body. The rhabdoid cytomorphology is believed to be the expression of a very primitive malignant cell. (From Holland et al., Cancer Medicine, 3d ed, p2210)	0	2.11	1	0
Alopecia Cicatrisata [description not available]	0	2.11	1	0
Dysgeusia A condition characterized by alterations of the sense of taste which may range from mild to severe, including gross distortions of taste quality.	0	7.11	1	0
Nail Diseases Diseases of the nail plate and tissues surrounding it. The concept is limited to primates.	0	2.11	1	0
Alopecia Absence of hair from areas where it is normally present.	0	7.11	1	0
Genetic Predisposition [description not available]	0	4.97	4	0
Bleeding [description not available]	0	2.11	1	0
Hemorrhage Bleeding or escape of blood from a vessel.	0	2.11	1	0
Acute Liver Injury, Drug-Induced [description not available]	0	3.04	1	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	0	3.04	1	0
Angiogenesis, Pathologic [description not available]	0	3.41	2	0
Cranial Nerve II Diseases [description not available]	0	2.13	1	0
Optic Nerve Diseases Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.	0	2.13	1	0
Carcinoma, Non-Small Cell Lung [description not available]	0	4.48	2	2
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	1	6.48	2	2
Abdominal Neoplasms New abnormal growth of tissue in the ABDOMEN.	0	2.13	1	0
Carcinoma, Epidermoid [description not available]	0	3.87	2	1
Cholera Infantum [description not available]	0	4.8	2	1
Blood Diseases [description not available]	0	3.51	1	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	1	5.87	2	1
Hematologic Diseases Disorders of the blood and blood forming tissues.	0	3.51	1	1
Carcinoma, Large Cell A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)	0	3.51	1	1
Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.	0	2.15	1	0
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	0	2.06	1	0
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	0	2.07	1	0
Cardiovascular Stroke [description not available]	0	2.07	1	0
Blood Clot [description not available]	0	2.07	1	0
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	0	7.07	1	0
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	0	7.07	1	0
Pyrexia [description not available]	0	2.49	2	0
Fever An abnormal elevation of body temperature, usually as a result of a pathologic process.	0	2.49	2	0
Disease Resistance The capacity of an organism to defend itself against pathological processes or the agents of those processes. This most often involves innate immunity whereby the organism responds to pathogens in a generic way. The term disease resistance is used most frequently when referring to plants.	0	2.99	1	0
Complication, Postoperative [description not available]	0	2.99	1	0
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	0	2.99	1	0

cabazitaxel

Description

Cross-References

Synonyms (84)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (1)

Protein Targets (5)

Potency Measurements

Biological Processes (30)

Molecular Functions (5)

Ceullar Components (2)

Bioassays (86)

Research

Studies (582)

Market Indicators

Research Demand Index: 64.35

Study Types

cabazitaxel

Description

Cross-References

Synonyms (84)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (1)

Protein Targets (5)

Potency Measurements

Biological Processes (30)

Molecular Functions (5)

Ceullar Components (2)

Bioassays (86)

Research

Studies (582)

Market Indicators

Research Demand Index: 64.35

Study Types

Related Drugs (140)

Related Conditions (187)